Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate

Ohno, Ryuzo; Asou, Norio; Ohnishi, Kazunori

doi:10.1038/sj.leu.2403031

Cited by 140 publications

(106 citation statements)

References 74 publications

Supporting

Mentioning

101

Contrasting

Unclassified

Order By: Relevance

“…11 Clinical evidence, including our reports, also supported the independence of P-gp and ATRA-resistance. 13 Taking these data into consideration, GO is predictably effective on ATRAresistant APL unless P-gp is expressed.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

et al. 2005

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…In APL, the drug resistance, which has been studied and discussed previously, might be built up by multiple causes and procedures. 8,13 Further studies on APL should be performed from many directions. It is also important to determine the optimal dosage of these drugs as well as the optimal timing of their administration.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

et al. 2005

Self Cite

View full text Add to dashboard Cite

“…For in vivo treatment with ATRA, the procedures were performed as previously described [38]. Briefly, SYO-1 (5 9 10 6 ) cells suspended in 100 mL of PBS were subcutaneously injected into the hind flank of male BALB/c nu/nu athymic mice at 5 weeks of age (Japan SLC, Hamamatsu, Japan).…”

Section: Methodsmentioning

confidence: 99%

Neuronal Differentiation of Synovial Sarcoma and Its Therapeutic Application

Ishibe

Nakayama

Aoyama

et al. 2008

Clin Orthop Relat Res

View full text Add to dashboard Cite

Synovial sarcoma is a rare sarcoma of unknown histologic origin. We previously reported the gene expression profile of synovial sarcoma was closely related to that of malignant peripheral nerve sheath tumors, and the fibroblast growth factor (FGF) signal was one of the main growth signals in synovial sarcoma. Here we further demonstrate the neural origin of synovial sarcoma using primary tumors and cell lines. The expression of neural tissuerelated genes was confirmed in synovial sarcoma tumor tissues, but the expression of some genes was absent in synovial sarcoma cell lines. Treatment of synovial sarcoma cell lines with BMP4 or FGF2 enhanced or restored the expression of neural tissue-related genes and induced a neuron-like morphology with positive Tuj-1 expression. Treatment with all-trans-retinoic acid also induced the expression of neural tissue-related genes in association with growth inhibition, which was not observed in other cell lines except a malignant peripheral nerve sheath tumor cell line. A growth-inhibitory effect of all-trans-retinoic acid was also observed for xenografted tumors in athymic mice. The simultaneous treatment with FGF signal inhibitors enhanced the growth-inhibitory effect of all-trans-retinoic acid, suggesting the combination of growth signaling inhibition and differentiation induction could be a potential molecular target for treating synovial sarcoma.

show abstract

“…[6][7][8][9][10] However, the disease may relapse with resistance to further ATRA and chemotherapy treatments. The discovery that treatment with arsenic trioxide (As 2 O 3 ) induces durable remission not only in primary cases, but also in APL patients in relapse after ATRA or chemotherapy, has provided a novel therapy for APL patients.…”

Section: Introductionmentioning

confidence: 99%

Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death

et al. 2005

View full text Add to dashboard Cite

Acute promyelocytic leukemia (APL) is efficiently treated with a cell differentiation inducer, all-trans retinoic acid (ATRA). However, a significant percentage of patients still develop resistance to this treatment. Recently, arsenic trioxide (As 2 O 3 ), alone or in combination with ATRA, has been identified as an alternative therapy in patients with both ATRA-sensitive and ATRA-resistant APL. Previous investigations restricted the mechanism of this synergism to the modulation and/or degradation of PML-RARa oncoprotein through distinct pathways. In this study, using several ATRA maturation-resistant APL cell lines, we demonstrate in vitro that the success of ATRA/As 2 O 3 treatment in APL pathology can be explained, at least in part, by a synergistic effect of these two drugs in triggering downregulation of telomerase efficient enough to cause telomere shortening and subsequent cell death. Such long-term low-dose combinatorial therapy strategies, developed also to avoid acute side effects, reinforce the notion that the antitelomerase strategy, based on a combination of active agents, should now be considered and evaluated not only in APL but also in other malignancies.

show abstract

Treatment of acute promyelocytic leukemia: strategy toward further increase of cure rate

Cited by 140 publications

References 74 publications

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells

Neuronal Differentiation of Synovial Sarcoma and Its Therapeutic Application

Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death

Contact Info

Product

Resources

About